May 26, 2017


GSK accepting proposals for the 2017 Duke-DPAc New Target Screening until June 30th

Program Highlights

  • Receive $150K of co-funding from DPAc and Duke to pursue translational research studies and/or assay development around the proposed target.
  • Access to GSK’s world-leading high throughput screening platforms (e.g. ~2 million compound High Throughput Screen (HTS) and >10 billion Encoded Library Technology (ELT) compounds).
  • Proposals can be submitted via a simple one-page form, which can be downloaded here. Please submit the completed form to Bryan Baines ( who will then forward it to GSK. A panel of DPAc scientists will review and provide specific feedback on every proposal received.
  • Collaborate with drug discovery experts to screen your target against GSK’s extensive compound collection and potentially access new research tools to further your research.

If you have questions about the program, please contact Bryan Baines ( in the Office of Licensing and Ventures at Duke University.